Obesity (Silver Spring, Md.)最新文献_第4页

Effects of Whole-Body Cryotherapy Combined With Conventional Obesity Management Versus Obesity Management Alone: A Clinical Trial. 全身冷冻疗法联合常规肥胖治疗与单独肥胖治疗的效果：一项临床试验。

Obesity (Silver Spring, Md.) Pub Date : 2025-09-03 DOI: 10.1002/oby.70019

Jari E Karppinen, Laura Suojanen, Sini Heinonen, Sanna Kaye, Birgitta W van der Kolk, James W White, Janne Orava, Seung Hyuk T Lee, Eugené Dillon, Maheswary Muniandy, Aila Rissanen, Carel W le Roux, Neil Docherty, Päivi Pajukanta, Kirsi A Virtanen, Kirsi H Pietiläinen

{"title":"Effects of Whole-Body Cryotherapy Combined With Conventional Obesity Management Versus Obesity Management Alone: A Clinical Trial.","authors":"Jari E Karppinen, Laura Suojanen, Sini Heinonen, Sanna Kaye, Birgitta W van der Kolk, James W White, Janne Orava, Seung Hyuk T Lee, Eugené Dillon, Maheswary Muniandy, Aila Rissanen, Carel W le Roux, Neil Docherty, Päivi Pajukanta, Kirsi A Virtanen, Kirsi H Pietiläinen","doi":"10.1002/oby.70019","DOIUrl":"https://doi.org/10.1002/oby.70019","url":null,"abstract":"Objective: To investigate whether whole-body cryotherapy (WBC) enhances weight loss, brown adipose tissue (BAT) activation, and metabolic outcomes during obesity management.Methods: Nineteen adults with obesity were assigned to a 12-month lifestyle-based obesity management intervention with 28 WBC sessions (-110°C, 3-4 min, ~2 × week) over the first 5 months (CRYO, n = 10) or the intervention without WBC (CON, n = 9). The primary outcome was weight loss (5 and 12 months). Secondary outcomes included BAT glucose uptake and whole-body energy expenditure during cold stimulation (5 months), clinical parameters, subcutaneous adipose tissue transcriptomics, and skeletal muscle proteomics (5 and 12 months).Results: Weight loss in the CRYO group was 11.9% at 5 months and 9.9% at 12 months, compared to 11.5% and 8.0% in the CON group (p ≥ 0.54 for between-group differences). No significant between-group differences appeared in BAT glucose uptake, energy expenditure, adipose tissue transcriptomics, or skeletal muscle proteomics changes. However, at 5 months, the CRYO group showed greater reductions in fasting glucose (0.41 mmol/L, p = 0.026) and LDL cholesterol (0.44 mmol/L, p = 0.034).Conclusions: WBC did not significantly enhance weight loss, activate BAT, or alter most metabolic responses during conventional obesity management. Further research is needed to confirm whether WBC benefits glucose and cholesterol metabolism.Trial registration: ClinicalTrials.gov: NCT01312090.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Insulin Sensitivity in Lean Mass Changes During Weight Loss With or Without Exercise. 胰岛素敏感性在运动或不运动减肥期间瘦质量变化中的作用。

Obesity (Silver Spring, Md.) Pub Date : 2025-09-02 DOI: 10.1002/oby.70010

Ciera L Bartholomew, Catia Martins, Barbara Gower

{"title":"The Role of Insulin Sensitivity in Lean Mass Changes During Weight Loss With or Without Exercise.","authors":"Ciera L Bartholomew, Catia Martins, Barbara Gower","doi":"10.1002/oby.70010","DOIUrl":"https://doi.org/10.1002/oby.70010","url":null,"abstract":"Objective: This study aimed to investigate the association between baseline insulin sensitivity (SI) and changes in total lean mass (LM) and appendicular LM (ALM) during a diet-induced weight loss program with or without exercise.Methods: We conducted a secondary data analysis from a controlled weight loss study in premenopausal women with overweight aged 21-41. Women were randomized into three groups: diet-only, diet plus aerobic exercise, or diet plus resistance exercise. Body composition was assessed using dual-absorptiometry X-ray and SI using an intravenous glucose tolerance test. Multiple linear regression was used to determine if baseline SI was predictive of changes in total LM and ALM.Results: There were significant group-SI interactions on changes in total LM (β = 0.474, p = 0.003, adjusted r2 = 0.371) and ALM (β = 0 0.462, p = 0.009, adjusted r2 = 0.231) after adjusting for covariates, indicating that greater baseline SI was associated with less LM loss only in women who did not exercise.Conclusions: Higher baseline SI is associated with greater retention of LM when weight loss is induced with diet alone, but not when exercise (aerobic or resistance) is included. This reinforces the importance of including exercise in all weight loss interventions.Trial registration: ClinicalTrials.gov identifier: NCT00067873.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduced Gastric Mucosal Innervation in Obesity: A Biomarker Predicting Remission of Diabetes After Bariatric Surgery. 肥胖患者胃粘膜神经支配减少：一个预测减肥手术后糖尿病缓解的生物标志物。

Obesity (Silver Spring, Md.) Pub Date : 2025-09-02 DOI: 10.1002/oby.70012

Po-Jen Yang, Ping-Huei Tseng, Koping Chang, Chi-Chao Chao, Jing-Jung Wei, Wei-Shiung Yang, Chi-Ling Chen, Hui-Fang Ke, Po-Chu Lee, Chiung-Nien Chen, Ming-Tsan Lin, Sung-Tsang Hsieh

{"title":"Reduced Gastric Mucosal Innervation in Obesity: A Biomarker Predicting Remission of Diabetes After Bariatric Surgery.","authors":"Po-Jen Yang, Ping-Huei Tseng, Koping Chang, Chi-Chao Chao, Jing-Jung Wei, Wei-Shiung Yang, Chi-Ling Chen, Hui-Fang Ke, Po-Chu Lee, Chiung-Nien Chen, Ming-Tsan Lin, Sung-Tsang Hsieh","doi":"10.1002/oby.70012","DOIUrl":"10.1002/oby.70012","url":null,"abstract":"Objective: Obesity is a risk factor for dysregulated gastric function and peripheral nerve degeneration. This study aimed to investigate the impact of obesity on the structural pathology and morphometry of gastric mucosal innervation.Methods: Sixty patients with obesity (30 with and 30 without type 2 diabetes) undergoing sleeve gastrectomy and 15 healthy controls were recruited. Gastric mucosal nerve terminals at the antrum were immunostained using protein gene product 9.5 and quantified using stereology-based morphometry to determine gastric mucosal innervation density (GMID).Results: Patients with obesity had lower GMID than control participants (464.0 ± 157.5 vs. 789.7 ± 188.9 mm/mm3, p < 0.001). There was a further reduction in GMID in patients with diabetes than in those without diabetes (406.8 ± 113.9 vs. 521.2 ± 175.3 mm/mm3, p < 0.001). GMID was significantly associated with BMI and glycemic parameters (fasting blood glucose, HbA1c) in multilinear regression analyses. One year post surgery, 19 patients achieving diabetes remission showed higher GMID compared to those without remission (444.8 ± 111.5 mm/mm3 vs. 341.1 ± 88.1 mm/mm3, p = 0.012). GMID remained an independent predictor for diabetes remission in multivariable logistic regression analyses.Conclusions: Gastric mucosal innervation was significantly reduced by the synergistic effects of obesity and diabetes. GMID could serve as a potential biomarker for predicting diabetes remission following bariatric surgery.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Weight Change and Accumulation of Chronic Conditions in Women During Reproductive Years. 育龄期妇女体重变化与慢性疾病积累

Obesity (Silver Spring, Md.) Pub Date : 2025-09-02 DOI: 10.1002/oby.70023

Mohammad R Baneshi, Annette Dobson, Gita D Mishra

{"title":"Weight Change and Accumulation of Chronic Conditions in Women During Reproductive Years.","authors":"Mohammad R Baneshi, Annette Dobson, Gita D Mishra","doi":"10.1002/oby.70023","DOIUrl":"10.1002/oby.70023","url":null,"abstract":"Objective: We examined the association between BMI change and risk of multimorbidity among women of reproductive age and estimated annual weight gain before and after diagnosis of chronic conditions.Methods: Data were from 8895 women in the Australian Longitudinal Study on Women's Health who had no chronic conditions at baseline. BMI from Survey 1 (ages 18-23) and Survey 3 (ages 25-30) defined BMI change categories. Linear mixed models estimated annual weight gain from Survey 1 to Survey 9 (ages 43-49).Results: Compared to stable normal BMI, stable obesity and increasing BMI were associated with a higher risk of incident multimorbidity (OR = 1.79 [95% CI: 1.11, 2.90] and 1.34 [1.10, 1.63]). Women who remained free of chronic conditions gained 0.50 kg (0.48, 0.52) annually. Women with one condition gained 0.54 kg (0.52, 0.56): 0.55 (0.53, 0.57) before and 0.54 (0.51, 0.57) after diagnosis. Those with multimorbidity gained 0.65 kg (0.63, 0.67): 0.75 kg (0.70, 0.80) before the first, 0.60 kg (0.56, 0.64) between the first and second, and 0.57 kg (0.53, 0.61) after the second condition.Conclusions: Although weight gain declined after diagnosis, it remained higher than among women without conditions, underscoring the need for improved post-diagnosis weight management.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice. 西马鲁肽辅助治疗袖胃切除术的疗效：一项小鼠概念验证研究。

Obesity (Silver Spring, Md.) Pub Date : 2025-09-02 DOI: 10.1002/oby.70003

Samuel Frey, Clément Louis-Gaubert, Amélie Thouzeau, Lola Cossé, Victoria Lorant, Xavier Prieur, Laurent Flet, Bertrand Cariou, Claire Louis Blanchard, Cédric Le May

{"title":"Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice.","authors":"Samuel Frey, Clément Louis-Gaubert, Amélie Thouzeau, Lola Cossé, Victoria Lorant, Xavier Prieur, Laurent Flet, Bertrand Cariou, Claire Louis Blanchard, Cédric Le May","doi":"10.1002/oby.70003","DOIUrl":"10.1002/oby.70003","url":null,"abstract":"Objective: This proof-of-concept study evaluated the impact of adding semaglutide as an adjuvant therapy to sleeve gastrectomy (SG) on weight loss and metabolic outcomes in obese mice.Methods: C57Bl6/J male received for 12 weeks high-fat diet and 20% fructose-enriched water, then they were randomized to undergo SG or a Sham surgery and were subsequently treated with either semaglutide or a vehicle for 8 weeks. Mice were weighed weekly, and food intake, plasma glucose levels, and adipose tissue weights were measured.Results: Both SG and semaglutide alone significantly reduced body weight compared with Sham surgery (-22.9%, p = 0.049 and -28.2%, p = 0.003, respectively). SG and semaglutide combination resulted in the greatest reduction (-30.0%, p = 0.003). Food intake was only significantly decreased in the semaglutide group. Although SG has no significant effect, semaglutide alone and in association with SG significantly decreased the plasma glucose concentration. The combination also led to a significant reduction in plasma cholesterol levels (-37.5% ± 4.8% vs. 5.6% ± 6.8%, p = 0.023). Liver steatosis was reduced in all treated groups.Conclusions: Adding semaglutide to SG potentiates weight loss and metabolic benefits of surgery in obese mice, but no more than with semaglutide alone. These findings support further investigation of combined surgical and pharmacological approaches in obesity treatment.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Update on the American Board of Obesity Medicine (ABOM): 2017-2024. 美国肥胖医学委员会（ABOM）最新报告：2017-2024。

Obesity (Silver Spring, Md.) Pub Date : 2025-09-02 DOI: 10.1002/oby.70013

Brianna Johnson-Rabbett, Tirissa J Reid, Edmond P Wickham, Judith Korner, Dana R Brittan, Kimberly A Gudzune

{"title":"An Update on the American Board of Obesity Medicine (ABOM): 2017-2024.","authors":"Brianna Johnson-Rabbett, Tirissa J Reid, Edmond P Wickham, Judith Korner, Dana R Brittan, Kimberly A Gudzune","doi":"10.1002/oby.70013","DOIUrl":"https://doi.org/10.1002/oby.70013","url":null,"abstract":"Objective: This study aimed to describe the characteristics of American Board of Obesity Medicine (ABOM) physician diplomates over the last 8 years (2017-2024).Methods: Using the ABOM database, we conducted a cross-sectional study of physicians who achieved initial ABOM certification between 2017 and 2024. Characteristics included demographics, primary medical specialty, years of obesity medicine experience, patient population, and practice setting. We conducted descriptive analyses and compared current characteristics with estimates extracted from the published ABOM 5-year report (2012-2016).Results: Overall, 8640 physicians achieved initial ABOM certification between 2017 and 2024; 2068 achieved certification between 2012 and 2016. Between the 2012-2016 and 2017-2024 groups, notable differences were increases in physicians under age 40 years (22.7% vs. 47.6%, respectively), women (52.8% vs. 64.0%, respectively), and practicing obesity medicine for less than 2 years at initial certification (40.2% vs. 68.3%, respectively). The most common primary medical specialties were internal medicine (32.4%), family medicine (29.2%), and internal medicine subspecialties (14.2%).Conclusions: We found that recent ABOM diplomates are likely entering the field earlier in their careers and with fewer years of obesity medicine experience than the initial group. Future investigation is needed to understand how ABOM and other obesity organizations can best support these physicians in their transition to obesity medicine clinical practice.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CRISPLD2: A Weight Loss-Induced Adipokine With Antifibrotic Capabilities in Adipose Tissue. CRISPLD2：一种在脂肪组织中具有抗纤维化能力的减肥诱导脂肪因子。

Obesity (Silver Spring, Md.) Pub Date : 2025-08-28 DOI: 10.1002/oby.70034

David Mendoza, Jacqueline M Stephens

引用次数: 0

Using Time-Weighted Averages of Total Daily Energy Expenditure to Estimate Energy Intake During a Weight Loss Intervention. 使用每日总能量消耗的时间加权平均值来估计减肥干预期间的能量摄入。

Obesity (Silver Spring, Md.) Pub Date : 2025-08-28 DOI: 10.1002/oby.70008

Matthew J Breit, Zhaoxing Pan, Danielle M Ostendorf, Jared H Dahle, Victoria A Catenacci, Seth A Creasy, Edward L Melanson

{"title":"Using Time-Weighted Averages of Total Daily Energy Expenditure to Estimate Energy Intake During a Weight Loss Intervention.","authors":"Matthew J Breit, Zhaoxing Pan, Danielle M Ostendorf, Jared H Dahle, Victoria A Catenacci, Seth A Creasy, Edward L Melanson","doi":"10.1002/oby.70008","DOIUrl":"https://doi.org/10.1002/oby.70008","url":null,"abstract":"Objective: The doubly labeled water (DLW) intake-balance method estimates energy intake (EI) during weight loss using the time-weighted average of total daily energy expenditure (TDEE) and changes in body energy stores. Because TDEE declines rapidly during the early phase of weight loss, an early additional measurement is recommended. This study aimed to develop regression models that estimate time-weighted TDEE using fewer interim measurements and determine if EI accuracy is maintained during a 12-month weight loss intervention.Methods: Data from a behavioral weight loss intervention (Dietary Caloric Restriction versus intermittent Fasting Trial, \"DRIFT\") were used. TDEE, body weight, and body composition were measured at months 0, 1, 6, and 12. Regression models using only two or three time points were used to estimate time-weighted TDEE at months 6 and 12, respectively. Models were validated using bootstrap sampling, and time-weighted TDEE and percent caloric restriction (% CR) were compared to a reference approach.Results: Models demonstrated strong predictive performance (R2 = 0.911-0.982). Limits of agreement with the reference model were 121.1-274.5 kcal/day for TDEE and 4.5%-10.3% for % CR, without significant bias.Conclusions: Using a regression modeling approach, we demonstrate the DLW intake-balance method maintains accuracy during weight loss without early-phase TDEE measurements.Trial registration: ClinicalTrials.gov identifier: NCT03411356.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CRISPLD2, a novel insulin-sensitizing adipokine that alters adipocyte size. CRISPLD2，一种改变脂肪细胞大小的新型胰岛素致敏脂肪因子。

Obesity (Silver Spring, Md.) Pub Date : 2025-08-26 DOI: 10.1002/oby.24342

Beth A Griesel, Kylie Williams, Nagib Ahsan, Philipp E Scherer, Ann Louise Olson, David P Sparling

{"title":"CRISPLD2, a novel insulin-sensitizing adipokine that alters adipocyte size.","authors":"Beth A Griesel, Kylie Williams, Nagib Ahsan, Philipp E Scherer, Ann Louise Olson, David P Sparling","doi":"10.1002/oby.24342","DOIUrl":"https://doi.org/10.1002/oby.24342","url":null,"abstract":"Objective: Both obesity and adipose tissue fibrosis are associated with insulin resistance, which can improve with weight loss. We previously found increased adipocyte-specific secretion of the novel adipokine CRISPLD2 during weight loss. In this study, we further explore the function of adipose CRISPLD2, which others suggest may regulate inflammation and fibrosis in a variety of tissues.Methods: We designed mice with adipose-specific doxycycline-inducible overexpression of CRISPLD2 (CLD2AD) to assess adipose-specific effects on tissue structure and function on chow or high-fat diets. The effects of prolonged excess CRISPLD2 were determined after 7 months, including stromal vascular fraction analysis by single-cell RNA-seq. CRISPLD2 cell surface signaling was explored in 3T3-L1 adipocytes via transwell assays, and adipocyte binding partners were determined in unbiased binding screening by mass spectrometry.Results: CLD2AD mice had decreased adipocyte size but unchanged fat mass. Long-term CRISPLD2 overexpression led to downregulation of collagen transcription and decreased fibrosis. CRISPLD2 induced Ifng transcription in adipocytes in vitro and bound multiple adipocyte cell surface proteins, including nucleolin. Finally, obese CLD2AD mice had decreased adipocyte size and improved glucose tolerance, with no change in fat mass.Conclusions: These data suggest a model wherein CRISPLD2 can both regulate adipose tissue fibrosis and improve insulin sensitivity.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes. 胰高血糖素样肽-1受体激动剂与老年2型糖尿病患者癌症风险的关系

Obesity (Silver Spring, Md.) Pub Date : 2025-08-21 DOI: 10.1002/oby.24366

Ying Lu, Hao Dai, Huilin Tang, William T Donahoo, Thomas J George, Ramon C Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D Licht, John M Allen, Kelvin P Lee, Jingchuan Guo, Jiang Bian

{"title":"Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes.","authors":"Ying Lu, Hao Dai, Huilin Tang, William T Donahoo, Thomas J George, Ramon C Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D Licht, John M Allen, Kelvin P Lee, Jingchuan Guo, Jiang Bian","doi":"10.1002/oby.24366","DOIUrl":"10.1002/oby.24366","url":null,"abstract":"Objective: The real-world evidence on the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cancer risk remains limited and mixed.Methods: In 2013-2020 national Medicare claims data, we included cancer-naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP-1 RA, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase 4 inhibitor (DPP4i) and conducted 1:1 propensity score matching for confounding adjustment. Cox proportional hazards models were used to estimate hazard ratios (HR) of nine obesity-associated cancers (thyroid, pancreatic, bladder, colorectal, lung, kidney, breast, endometrial, and prostate cancer).Results: In the matched GLP-1RA versus SGLT2i cohort (n = 21,362 pairs), GLP-1RA users had similar overall cancer risk with SGLT2i users (HR, 1.03 [95% CI, 0.95-1.12]), but GLP-1RAs were associated with an increased kidney cancer risk (HR, 1.43 [1.06-1.92]). In the matched GLP-1RA versus DPP4i cohort (n = 20,962 pairs), the GLP-1RA versus DPP4i comparison showed no significant difference in overall cancer risk (HR, 0.96 [0.89-1.04]) but revealed a significantly elevated endometrial cancer risk (HR, 1.55 [1.01-2.37]).Conclusion: GLP-1RAs might be associated with an increased risk of certain cancer types. Future studies are needed to validate the potential tumorigenic risk associated with GLP1-RAs.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0